Just before leaving office, the Biden administration has announced costly GLP-1 drugs often used for weight loss are among the 15 medications listed in the next round of Medicare price negotiations.

The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare Part-D for price negotiations, the next round of negotiations under the Inflation Reduction Act passed by President Joe Biden in 2022.

The Biden administration on Friday released its next round of prescription drugs selected for Medicare price negotiations, which includes Ozempic.

Drug prices are up for negotiation on 15 Medicare Part D prescription drugs, including popular weight loss drugs such as Ozempic.

CHARLOTTESVILLE, Va. (WVIR) - Weight loss and diabetes drugs such as Ozempic and Wegovy could possibly be covered by Medicare in the future. It was listed with 15 other drugs to have a price negotiated. The government and manufacturers will have to negotiate a deal for the popular weight loss drugs.

The hugely popular medications Ozempic and Wegovy​, used for diabetes and weight loss, will be included in the next round of talks to negotiate lower Medicare drug prices.

Eli Lilly and other drugmakers are reportedly planning to urge the Trump administration to pause Medicare drug-price negotiations that were put in place by the Biden administration's Inflation Reduction Act (IRA). "They need to fix [the IRA]," Eli Lilly CEO Dave Ricks told Bloomberg at the JPMorgan Healthcare Conference in San Francisco.

Tripling the dosage of the Wegovy weight-loss drug leads to more weight loss, Novo Nordisk said Friday. The Danish drugmaker announced results from a Phase 3B trial of semaglutide at a 7.2 milligram dosage,

Read More: Patients Are Suing Over Alleged Side Effects of Weight-Loss Drugs

Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated prices for Ozempic, Wegovy, and Rybelsus will be. In Medicare's negotiations for 2026, the new prices achieved an average of 22% savings.

As weight loss medications like Ozempic and Wegovy become increasingly popular, questions arise about whether the nation is approaching pea